AUSTIN, Texas – Genprex , Inc. (NASDAQ: NASDAQ:), a clinical-stage gene remedy firm, has been granted a brand new patent by the Singapore Patent Workplace for its lead drug candidate, Reqorsa® Gene Remedy, when used along side anti-PD-1 antibodies, extending safety by way of 2037.
This latest patent award bolsters the corporate’s mental property rights past the prevailing patents it holds in a number of nations, together with the U.S., Japan, and China, for the mix use of REQORSA with immune checkpoint inhibitors.
Senior VP of Mental Property and Licensing at Genprex, Thomas Gallagher, Esq., emphasised the importance of this patent for the corporate’s strategic positioning in Asia, significantly because of the excessive prevalence of lung most cancers within the area. In line with GLOBOCAN, Asia accounted for 63% of world new lung most cancers circumstances in 2022, highlighting the significance of this marketplace for Genprex’s therapies.
The Acclaim-3 scientific trial, which mixes REQORSA with Genentech’s Tecentriq®, is at present in Part 1/2 as a upkeep remedy for small cell lung most cancers sufferers who’ve skilled tumor development after preliminary therapy.
Genprex’s broader mission includes growing gene therapies for giant affected person populations with most cancers and diabetes who’ve restricted therapy choices. Its oncology program employs the Oncoprex® Supply System to manage genes that produce tumor-suppressing proteins.
Whereas the corporate encourages buyers and shareholders to observe its progress by way of numerous communication channels, warning is suggested relating to forward-looking statements.
Genprex, Inc. has skilled vital adjustments in management and company governance. Ryan M. Confer has been confirmed as President, CEO, and CFO, whereas Catherine Vaczy’s employment as Govt VP has been terminated. M. Longnecker was elected as a Class I director and WithumSmith+Brown, PC was ratified because the impartial registered public accounting agency.
On the scientific entrance, Genprex reported optimistic preclinical information for its Reqorsa® Immunogene Remedy and NPRL2 gene remedy. The corporate has additionally expanded its Acclaim-3 scientific trial websites to speed up affected person enrollment and supply broader entry to its Reqorsa® Immunogene Remedy for treating extensive-stage small cell lung most cancers.
When it comes to analyst protection, H.C. Wainwright initiated protection of Genprex’s inventory with a Purchase score, signaling a optimistic outlook for the corporate’s gene remedy strategy to treating lung most cancers.
Moreover, Jose A. Moreno Toscano has been named the non-executive Chairman of the Board, following the sudden loss of life of co-founder and former Chairman Rodney Varner.
InvestingPro Insights
Amidst the strategic developments in Genprex’s mental property portfolio, the corporate’s monetary standing presents a combined image in accordance with latest metrics from InvestingPro. With a market capitalization of simply $3.26 million, Genprex is taken into account a small-cap firm, which may typically imply larger volatility and danger for buyers. The corporate’s monetary well being is mirrored in its price-to-book ratio, which stands at a modest 0.75 as of the final twelve months main as much as Q2 2024. This implies that the corporate’s market valuation is comparatively near its internet asset worth, which generally is a signal of undervaluation.
Nonetheless, the street to profitability seems difficult, as evidenced by the corporate’s working revenue, which reveals a major lack of $26.29 million in the identical interval. This monetary pressure is additional highlighted by the inventory’s efficiency, with a steep year-to-date value complete return of -86.3%, indicating a tricky interval for the corporate’s shareholders. The value of Genprex’s inventory has additionally been buying and selling close to its 52-week low, at present at roughly 5% of its 52-week excessive, which may sign a possible entry level for buyers in the event that they imagine within the firm’s long-term prospects.
InvestingPro Ideas present extra context to the corporate’s financials, noting that Genprex holds more money than debt on its stability sheet, which is a optimistic indicator of economic stability. On the flip facet, the RSI means that the inventory is in oversold territory, probably indicating a shopping for alternative for contrarian buyers. For these contemplating a deeper dive into Genprex’s inventory, there are 11 extra InvestingPro Ideas out there, providing a complete evaluation that would information funding selections.
For extra detailed evaluation and extra InvestingPro Tips about Genprex, events can go to https://www.investing.com/professional/GNPX.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
